Investigating allosteric effects on the functional dynamics of [small beta]2-adrenergic ternary complexes with enhanced-sampling simulations by Saleh, N et al.
Chemical
Science
EDGE ARTICLE
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
4 
M
ar
ch
 2
01
7.
 D
ow
nl
oa
de
d 
on
 1
2/
06
/2
01
7 
17
:3
9:
00
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e. View Article Online
View Journal  | View IssueInvestigating alloaComputer-Chemie-Centrum and Interdisci
Friedrich-Alexander-Universita¨t Erlangen-N
Erlangen, Germany. E-mail: tim.clark@fau.
bDepartment of Chemistry, University Colleg
cInstitute of Structural and Molecular Biol
WC1E 6BT, UK
† Electronic supplementary informa
10.1039/c6sc04647a
Cite this: Chem. Sci., 2017, 8, 4019
Received 17th October 2016
Accepted 24th March 2017
DOI: 10.1039/c6sc04647a
rsc.li/chemical-science
This journal is © The Royal Society of Csteric eﬀects on the functional
dynamics of b2-adrenergic ternary complexes with
enhanced-sampling simulations†
Noureldin Saleh,a Giorgio Saladino,b Francesco Luigi Gervasio bc
and Timothy Clark *a
Signalling by G-protein coupled receptors usually occurs via ternary complexes formed under cooperative
binding between the receptor, a ligand and an intracellular binding partner (a G-protein or b-arrestin). While
a global rational for allosteric eﬀects in ternary complexes would be of great help in designing ligands with
speciﬁc eﬀects, the paucity of structural data for ternary complexes with b-arrestin, together with the
intrinsic diﬃculty of characterizing the dynamics involved in the allosteric coupling, have hindered the
eﬀorts to devise such a model. Here we have used enhanced-sampling atomistic molecular-dynamics
simulations to investigate the dynamics and complex formation mechanisms of both b-arrestin- and
Gs-complexes with the b2-adrenergic receptor (ADRB2) in its apo-form and in the presence of four
small ligands that exert diﬀerent allosteric eﬀects. Our results suggest that the structure and dynamics of
arrestin–ADRB2 complexes depend strongly on the nature of the small ligands. The complexes exhibit
a variety of diﬀerent coupling orientations in terms of the depth of the ﬁnger loop in the receptor and
activation states of ADRB2. The simulations also allow us to characterize the cooperativity between the
ligand and intracellular binding partner (IBP). Based on the complete and consistent results, we propose
an experimentally testable extended ternary complex model, where direction of the cooperative eﬀect
between ligand and IBP (positive or negative) and its magnitude are predicted to be a characteristic of
the ligand signaling bias. This paves the avenue to the rational design of ligands with speciﬁc functional
eﬀects.Introduction
G-protein coupled receptors (GPCRs) form activated ternary
signalling complexes with an agonist ligand and an intracellular
binding partner (IBP), which may be either a G-protein or
arrestin, to control a plethora of physiological processes. GPCRs
are targeted by over 30% of marketed drugs.1 Two crystal
structures have revealed the architecture of rhodopsin–arrestin
and b2-adrenergic receptor (ADRB2)–Gs signalling complexes.2,3
Still, the functional dynamics following the coupling mecha-
nism of IBPs to GPCRs and the role of allosteric eﬀects exerted
by the ligands, which cannot be inferred easily from the static
crystal structures, have only been partially addressed by spec-
troscopic studies.4plinary Center for Molecular Materials,
u¨rnberg, Na¨gelsbachstraße 25, 91052
de
e London, London WC1H 0AJ, UK
ogy, University College London, London
tion (ESI) available. See DOI:
hemistry 2017GPCR–ligands can eﬀect a variety of responses. They may not
only be agonists, antagonists, partial agonists or inverse agonists,
but can also aﬀect alternative signalling pathways (such as those
regulated by G-proteins or b-arrestin).5 This makes the rational
design of GPCR–ligands particularly complex as both the binding
aﬃnity and the possible functional bias need to be predicted and
designed. A global rational linking and explaining the various
allosteric eﬀects exerted by GPCR ligands remains elusive.
However, devising such a model is complicated by the intrinsic
diﬃculty of characterising the dynamic changes involved in the
allosteric coupling and by the limited structural information
available for b-arrestin ternary complexes. Indeed, only one
agonist has been crystallized in an active G-protein-coupled state
of ADRB2, and only rhodopsin was crystallized in complex with
visual arrestin.2,3 The lack of high-resolution models complicates
the design of ligands with specic allosteric eﬀects and signalling
bias.
Given the pivotal role of conformational dynamics in allo-
steric regulation,6,7 atomistic molecular-dynamics (MD) simu-
lations can be of great help in providing a mechanistic
understanding. MD simulations have successfully provided
atomistic insight into microsecond-scale processes ranging
from the deactivation of GPCRs, ligand–GPCR binding andChem. Sci., 2017, 8, 4019–4026 | 4019
Fig. 1 Ternary complex structure models of ADRB2 after 1 ms MD
reﬁnement Left: with its Gas. Right: including the chimeric ADRB2–V2R
C-terminus and in complex with b-arrestin.
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View Article Onlinenucleotide exchange in G-proteins.8–13 For instance, we recently
proposed a three-site mechanism for activation/antagonism of
the vasopressin receptor14 on the basis of extensive MD simu-
lations using metadynamics enhanced sampling15,16 and
showed that accurate binding free-energies can be obtained
from metadynamics simulations on GPCR-complexes. We have
also shown that enhanced-sampling simulations predict accu-
rate free energies of binding (approximately within 1 kcal
mol1) for all types of ligands (agonists, inverse agonists,
antagonists) binding to the b2-adrenergic receptor.17
In this work, we investigate the far more complex cooperative
eﬀects of small ligands and an intracellular binding partner (IBP)
forming a ternary complex.18 The extent of this cooperativity in
the perspective of the ternary complex model has been deter-
mined experimentally in few cases for the G-protein3,19–22 and for
arrestin,23–25 where the agonist aﬃnity is enhanced to its GPCR in
the presence of G-protein or arrestin.18 Building on our success-
ful experience with the modelling and simulations of ternary
complexes,26we have computed for the rst time the binding free
energies along a physical association coordinate in a ternary
complex (see Fig. 1 for modelled ADRB2 ternary complex struc-
tures). Our converged free energy landscapes allow us to quantify
the cooperative eﬀects of ligand and IBP on GPCR activation and
to reveal the allosteric coupling mechanisms and the criteria that
determine the eﬃcacy of biased ligands.We propose an extended
ternary complex model that can explain the functional bias of
GPCR ligands. Our model leads to quantitative predictions that
can be validated experimentally bymeasuring the cooperativity of
ligands with each IBP. Moreover, we also provide detailed
predictions on the eﬀects of the ligands on the structure of the
ADRB2–b arrestin complex.Results and discussion
We have chosen ADRB2 as an example of a structurally well-
characterized GPCR for which ample crystallographic4020 | Chem. Sci., 2017, 8, 4019–4026information is available and for which well-characterized ligands
have been co-crystallized. These include the full Gs-protein (Gs)/
arrestin native agonist isoprenaline, 1,27 the Gs/arrestin unselec-
tive antagonist alprenolol, 2,28 the Gs inverse agonist/arrestin
antagonist ICI-118,551, 3,28 and the Gs inverse agonist/arrestin
partial agonist, carvedilol, 4.29 Ternary ADRB2–Gas complexes for
these ligands were constructed based on the X-ray structure of
a ternary agonist (BI-167107)-ADBR2–Gs complex (PDB access code
3SN6).3 More complex modelling (see ESI Methods for more
details†) was employed to model the experimental construct used
by Wisler et al.30 to determine independent arrestin bias of
ADRB2–ligands, by combining structural information from both
crystal structures of the b-arrestin bound to the C-terminal peptide
of the vasopressin-2 receptor (PDB access code 4JQI)31 and the S-
arrestin-bound rhodopsin (PDB access code 4ZWJ).2 Our experi-
ence with transcription factors32 and GPCRs26,33–37 has shown that
long relaxation times of one or more ms are necessary to eliminate
the “memory eﬀect” associated with simulations that start from
homology models or from crystallographic structures far from the
equilibrium structure in solution.32 This conclusion does not
mean that the homology models can relax globally within the
equilibrium time because activation timescale of GPCRs are
known to be in the region of milliseconds.38 The results reported
below, however, strongly suggest that the locally relaxed structures
are suﬃcient to allow the subsequent metadynamics simulations
to sample the conformational changes associated with activation/
deactivation. Here, in accord with established practice,26,33–37,39,40
we have only included the a-subunit of the G-protein. This choice
has been shown to allow a reduction of the size of the system (and
a signicant increase in the sampling) while not compromising
the quality of the predictions. The chosenmodel is appropriate for
describing the Gas dissociation at the end of the signalling cycle,
aer the b- and g-subunits have detached. All models were relaxed
with long MD simulation (details are given in the ESI Methods).
Using massive enhanced-sampling MD simulations and
a generous computer time allocation on a Tier-0 supercom-
puter, we were able for the rst time to compute the converged
free-energy proles (FEPs) associated to the binding of ADBR2
to both Gas and b-arrestin, both in the absence and presence of
four ligands (see Fig. 2 and S1†). The free energy was computed
as a function of two variables describing the reaction coordi-
nate. The distance between transmembrane helices 3 and 6
(TM3–TM6) was used to indicate receptor activation. The tran-
sition between active (large distances) and inactive receptor
occurs at a distance of 1.4 nm.6 The coupling depth denes the
binding position of the IBP. The coupling depth is dened as
the z-component of the distance between Ca of Glu392 in the a5-
helix of Gas and Ca of Arg3.50 in ADRB2. As for our simulations
of the ligand-binding process,17 we make use of the orientation
of the receptor in the membrane, so that the z-distance, where
the z-direction is perpendicular to the membrane plane,
provides a convenient and eﬀective collective variable for the
IBP-binding process without restricting conformational or
orientational freedom in the membrane plane (see ESI Methods
for more details†). The bound Gs in the ternary complex crystal
structure corresponds to a coupling depth of 0.1 nm and one
larger than 2.5 nm to the uncoupled IBP. Each simulationThis journal is © The Royal Society of Chemistry 2017
Fig. 2 Free-energy contour maps for conformational changes along
Gas–ADRB2 coupling and activation in (A) apo form, (B) with the native
agonist isoprenaline and (C) the arrestin-biased agonist carvedilol with
diagrams describing the main intermediate complexes.
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
4 
M
ar
ch
 2
01
7.
 D
ow
nl
oa
de
d 
on
 1
2/
06
/2
01
7 
17
:3
9:
00
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinerequired approximately 7 ms to converge (see Fig. S3† for
sampling exhaustiveness) and by sampling multiple reactive
events, quantied the deactivation behaviour observed in
unbiased simulations8 (see Fig. S2†).
To our knowledge, these coupling simulations are the rst to
characterize G-protein or arrestin coupling to a GPCR for both
the apo- and ligand-bound receptors. The simulations, which
use proven enhanced-sampling algorithms and a reliable force
eld, reveal the activation state of the global energy minimum
for each ligand–ADRB2–b-arrestin and ligand–ARDRB2–Gas
complex and thus ligand-eﬀects on GPCR coupling and
signalling.
Both the apo- and ligand-bound ADRB2 complexes exhibit
a specic global minimum conformation, in which the TM3–TM6
distance indicates an active receptor and the IBP-coupling coor-
dinate a tightly bound Gas. Both the calculated apo-ADRB2–Gas
and isoprenaline–ADRB2–Gas binding free energies (approximately
11 to 12 kcal mol1, respectively, at 298 K) are consistent with
those determined experimentally for the opioid receptor to Gi (Kd¼
20 and 9 nM for the apo and agonist-bound receptors, respectively,
corresponding to 10.9 and 11.1 kcal mol1 at 298 K).41
The metadynamics simulations suggest a pattern of three
closely located local minima (structures shown in Fig. S4 of theThis journal is © The Royal Society of Chemistry 2017ESI†) less than 1 kcal mol1 apart for the binary apo-ADRB2–Gas
complex (at 1.6/0.1, 1.6/0.8 and 2.0/0.1 nm values for the TM3–
TM6 distance and coupling depth, respectively, see Fig. 2A). The
error bar on the free energy reconstruction does not allow us to
distinguish between three distinct minima and a single, wide
free energy basin. However, earlier simulations have suggested
plasticity of the conformations of ADRB2 and helix 5 of Gas to
allow ADRB2 to couple to both Gi and Gs,42 consistent with our
results. Agonist binding to the ADRB2–Gas complex (shown for
isoprenaline in Fig. 2B) converts this wide basin to a single
distinct minimum, indicating a cooperative allosteric commu-
nication between the coupling interface and the ligand-binding
pocket, since the ability of the ligands to stabilize a distinct
conformation was accompanied by a change in the aﬃnity
toward the coupling partner. The Gs inverse agonist carvedilol
exhibits a similar extended binding basin as found for the apo-
receptor (Fig. 2C).
Arrestin coupling is far more complex and heterogeneous
than for the G-protein. Coupling is initiated by the middle- and
c-loops of the arrestin (see Fig. 1 and S5† for the arrestin
complex structure) interacting with intracellular loop 2 (ICL2) of
the receptor. In contrast, within the arrestin, the nger-loop
retains its interaction with the polar core. The ligand-bound
simulations show a broad binding basin spread over a 2 nm
range of coupling depth and including both active and inactive
states (see Fig. 3A). This is consistent with the experimental
indications of conformational exibility observed in attempts to
crystallize rhodopsin-bound arrestin.2 This conformational
heterogeneity also characterizes the coupling to both the full-
agonist, isoprenaline (Fig. 3B), and the partial agonist, carve-
dilol (see Fig. 3C), neither of which coupled as intimately with
the nger loop as found in the arrestin–rhodopsin structure.
This deep nger loop conformer was found, however, for the
receptor bound to the antagonist alprenolol and inverse agonist
ICI 118551 (see Fig. 4, 3D and E). A recent uorescence spec-
troscopy study has provided evidence of this partially engaged
GPCR–arrestin complexes for both carvedilol and isoprenaline.43
Because the b-arrestin never separates fully from the phos-
phorylated chimeric C-terminus of the receptor in the metady-
namics simulations, we cannot estimate a coupling aﬃnity for
arrestin, only for Gas, for which a good correlation with exper-
iment is found (see Table 1 and Fig. S1†).
The simulations also reveal some structural changes during
the coupling to the IBP:
1. The C-terminus of the a5 helix of Gas uncoils in the
uncoupled states (coupling depth values > 2.5 nm), which
explains the absence of this region in the crystal structure of the
uncoupled trimeric G-protein (see Fig. S6,† PDB accession code:
1GOT44).
2. The isoprenaline-bound receptor then transits to either
active or inactive receptor conformations that interact addi-
tionally with b6-a4 secondary structural elements of Gas and
subsequently slowly with the a5 helix, whose C-terminal later
adopts a helix form (see diagrams II, III and IV in Fig. 2).
3. A recognition mechanism common to the two IBPs
involves interactions between ICL2 of the receptor and either
the aN-b1 secondary structural elements of Gas or the middleChem. Sci., 2017, 8, 4019–4026 | 4021
Fig. 3 Free-energy contour maps for conformational changes along
Gas–ADRB2 coupling and activation with (A) the apo-receptor, (B) the
arrestin-biased agonist isoprenaline and (C–E) the native agonist
carvedilol, the unbiased agonist alprenolol, and the unbiased inverse
agonist ICI-118,551 with diagrams describing the main intermediate
complexes.
Fig. 4 Structural comparison between the rhodopsin–S-arrestin
(green) and representative of the minima of the ADRB2–b-arrestin
complex at (A) 0 nm, (B) 0.8 nm and (C) 2.0 nm values on the coupling
reaction coordinate.
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View Article Onlineand C-loops of the b-arrestin (see Fig. S5† and diagram I in both
Fig. 2 and 3). The nger-loop of b-arrestin loses its helical form
at coupling depths > 2.5 nm (similar to the a5 helix of Gas) and
returns to an uncoiled conformation that interacts intimately
with the polar core of the arrestin.
The binding free energies computed following the protocol
of ref. 17 agree well with experiment. The root mean square
error (RMSE) is only 0.5 kcal mol1 (see Fig. S7 and Table S1 of
the ESI†). We extended the sampling to at least 1 ms to ensure4022 | Chem. Sci., 2017, 8, 4019–4026convergence and accuracy, where the FES changes less than 0.1
kcal mol1 in 200 ns of extra sampling (see Fig. S8†). The
metadynamics simulations reproduce the free energy of the
ligands as they progress from the extracellular region to the
orthosteric binding site, and thus allow us to calculate the
changes in both ligand- and IBP-binding energies caused by
cooperative binding between the two. The deepest minima
found for each ternary complex were rened with unbiasedThis journal is © The Royal Society of Chemistry 2017
Table 1 Calculated changes in the binding free energy for the four ligands (DDGligand) on binding an IBP and that for Gas (DDGGs) on binding
a ligand (kcal mol1). Where known, the experimental values are shown in parentheses
Ligand
Functional bias DDGligand
DDGGsGs b-Arrestin Gs b-Arrestin
1 Agonist Agonist 2.2 (2.8) 4.5 2
2 Antagonist Antagonist +0.3 +6.1 0
3 Inverse agonist Antagonist +1.5 (+1.5) +0.4 +4
4 Inverse agonist Partial agonist +2.5 3.6 +3
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View Article Onlinemolecular dynamics and our recently reported metadynamics
scheme17 used to scan the free-energy landscapes for the
binding of each ligand to apo-ADRB2, the Gs- and arrestin-
complexes. The agreement between the simulated complexes
and the available X-ray structures is shown in Fig. S9 of the ESI.†
Fig. 5 shows the binding free-energy proles obtained and Table
1 summarizes the eﬀects of Gas and b-arrestin on the ligand-
binding free energies and those of the ligands on Gas-binding.
The free-energy proles for ligand-binding (Fig. 5) show that
both Gas and arrestin aﬀect the binding energy of the most
stable binding site at approximately 0.8 nm on our reaction
coordinate, in accord with the ternary-complex model.18 In
particular, the experimentally known changes in binding free
energy of ligands 1 and 3 on G-protein binding are reproduced
well. Importantly Table 1 also shows that the direction in which
the IBP changes the ligand-binding energy relative to apo-
ADRB2 is indicative of the intrinsic activity of each ligand
with respect to the pathway controlled by the IBP, as dened by
Wisler et al.30
The simulations also provide atomistic details of the deter-
minants of functional bias. Both the Gs- and arrestin-activated
pockets of ADRB2–isoprenaline (TM3–TM6 distance; 1.6 nm ¼
active) show similar tightening in the binding pocket relative toFig. 5 Calculated free energy proﬁles for the four ligands. The binding
coordinate is deﬁned in the ESI Methods section.† Free energies are
given relative to the separated binding partners for apo-ADRB2 and the
Gas complex and as explained in the text for the b-arrestin complex.
Fig. 6 (a) Interactions between isoprenaline and ADRB2 that lead to
activation; common interactions for ternary Gs- and arrestin-stabilized
ADBR2–isoprenaline complexes (blue) and the binary-inactive ADRB2
(red): (b) comparison between the ternary Gs- and arrestin-stabilized
ADBR2–isoprenaline complexes (c) biased changes in carvedilol pose
between the Gs- (blue) and arrestin-stabilized poses (beige).
This journal is © The Royal Society of Chemistry 2017 Chem. Sci., 2017, 8, 4019–4026 | 4023
Fig. 7 Schematic diagram showing the classiﬁcation of the eﬀects of
ligands based on the change in the ligand binding free energy on
binding an IBP.
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View Article Onlinethe inactive-binary ADRB2 (TM3–TM6 distance; 0.9 nm ¼
inactive). The interaction of the agonist with S5.46, leads to an
inward movement of TM5, and the size of the alkylammonium
group allows the formation of a TM3–TM7 lock through inter-
actions of the agonist with D3.32, N7.39 and Y7.43 (see
Fig. 6(a)). Although these changes are similar for the G-protein
and arrestin ternary complexes, the two do show slight diﬀer-
ences. For the ternary Gs-complex, we nd a larger inward
movement of F192EC2, N6.55 and I7.36 and slightly more
outward orientation of T3.29, V3.36 and S5.46. Because,
however, isoprenaline is an agonist for both pathways, these
diﬀerences need not be signicant.
The biased arrestin partial-agonist/Gs inverse-agonist, carvedi-
lol provides an excellent demonstration that marginally diﬀerent
binding-pocket geometries are important for biased ligand func-
tion. Fig. 6(c) shows the subtle reorientations in the binding
pockets that lead to the change in the carvedilol pose. Both the
unbiased MD- and metadynamics simulations exhibit a 180 ip
of the phenoxyl moiety of carvedilol, 4, in the destabilized ternary
Gs–carvedilol–ADRB2 complex relative to both the higher-aﬃnity
binary ADRB2–carvedilol complex and the stabilized ternary
arrestin–ADRB2–carvedilol complex. This ip is caused by the
preferred inward movement of F192EC2 in the ternary Gs-complex.
It is thus responsible for the inverse agonistic eﬀect of carvedilol
toward G-protein coupling. Both arrestin and G-protein reoriented
residues lining the binding pocket and controlled the size of the
binding cavity. These changes in the ligand-binding pockets
provide a basis for the rational design of biased agonists.
Conclusions
Our simulations suggest that an interplay between ligand
binding and the coupling of either arrestin or G-protein can
provide a basis to understand and predict biased signalling. The
ligand changes the binding free-energy of the IBP, thus
controlling the signalling pathway regulated by IBP. This free-
energy change is due to an allosteric communication between
the ligand binding site and the IBPs.
ADRB2 belongs to the “class A” category of weakly arrestin-
recruiting GPCRs.45 Thus, determining the biased arrestin sig-
nalling of ligands on the wild type receptor accurately remains
a major experimental challenge.30 Our simulations therefore
provide a basis and much needed tool for rationalizing the
eﬀects and assisting drug design of biased GPCR–ligands. Our
ability to probe andmap the free energy and the exibility of the
coupling between ADRB2 and the IBPs promises to be an
important assisting factor for eﬀorts to determine the structures
of arrestin–GPCR complexes.
The simulations also provide another important tool for
SBDD; they can be used to classify the eﬀects of ligands on the
receptor. This is shown schematically in Fig. 7. The eﬀect of the
IBP on the binding energy of the ligand is indicative of the eﬀect
invoked by the ligand. Agonists and partial agonists increase
(make more negative) the binding free energy of the corre-
sponding IBP, antagonists leave it largely unaﬀected or decrease
it slightly, and inverse agonists decrease it strongly. Thus, based
on the eight functional eﬃcacies available for the four ligands,4024 | Chem. Sci., 2017, 8, 4019–4026we can conclude that comparison of ligand-binding free ener-
gies from simulations of binary and ternary complexes (three
simulations per ligand) allow us to identify the functional bias
of the ligand. This is shown schematically in Fig. 7. This simple
scheme allows ligands to be classied without resorting to
experiment.
Growing experimental evidence has connected the changes
upon IBP-coupling and the ligand binding sites.42,46 Designing
drugs for the active and inactive conformational states of
ADRB2 using virtual screening has shown potential in discov-
ering agonists.47,48 Our results indicate that using further
receptor states including the subtle changes between diﬀerent
IBPs may help discover functionally biased ligands. Our work
has shown the success of metadynamics-enhanced atomistic
simulations in probing those diﬀerent functional states, thus
further assessment for the ability of themethod to predict active
state GPCR conformations using the inactive crystal structures
might enforce the ability of the methods to reveal and predict
the multiple GPCR conformational states observed in spec-
troscopy49–51 and to reproduce their equilibrium probabilities.
Our simulations have provided the rst structural insight in
atomistic resolution of the partially-engaged arrestin complexes
to the ADRB2 that were characterized only recently.43
This work highlights the role of MD simulations as tools to
obtain information that would otherwise be hardly accessible to
experiment. This is both an important point and one that
requires careful validation by prediction of and comparison
with experimentally available data. We have shown that meta-
dynamics simulations of the type used here are able to calculate
ligand free energies of binding accurately, regardless of the
eﬃcacy of the ligand with remarkable agreement with experi-
ment as shown by the RMSE of only 0.5 kcal mol1. We suggest
that a further extension of the ternary complex model, where
the ligand bias towards either the G-protein or arrestin pathway
is controlled by the cooperative eﬀect induced by the coupling
partner on the ligand aﬃnity, as shown in Fig. 7. Our simula-
tions reveal the ne diﬀerence in the architecture of the ADRB2
in both arrestin- and Gs-stabilized states, thus design of ligands
with specic signalling properties can be achieved throughThis journal is © The Royal Society of Chemistry 2017
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View Article Onlinestabilization of these specic changes in each pocket. We also
suggest that Fig. 7 provides an excellent opportunity for blind
tests as to whether the simulations can predict both the binding
aﬃnity and the eﬃcacy (unbiased or biased, agonist, antago-
nist, inverse agonist) of unknown ligands based on their coop-
erative eﬀect to the IBP to match that from experiment.
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